Pharmafile Logo
Pharmafocus logo
Advanced Search
gsk_china_2_2_0_1

Cancer Research UK receives ‘success payment’ from GlaxoSmithKline

October 7, 2016
Medical Communications GSK, GlaxoSmithKline, University of Manchester, cancer research

CRT and the University of Manchester were rewarded financially for their collaboration developing molecules targeting cancer epigenetics. The agreement between …

News
top_ten_stories

Top Ten articles in the Pharma Industry this week

October 7, 2016
Medical Communications

The beginning of October has seen the failure of big drugs in clinical trials have a big knock-on effect for …

News
astrazeneca_building_white

AstraZeneca sells off third drug in five days

October 7, 2016
Medical Communications AstraZeneca, Cilag GmbH, Johnson & Johnson, Rhinocort Aqua

AstraZeneca have completed a third sell off in the course of one week by divesting rights to Rhinocort Aqua outside …

News

ICU Medical to acquire Pfizer’s global infusion therapy business in $1 billion deal

October 6, 2016
Medical Communications Hospira, ICU medical, Pfizer, acquisition, infusion

The $1 billion deal that will take place as ICU Medical Inc. take over Pfizer’s Hospira Infusion Systems will be …

News

“Incorrect classification” of EpiPen leads to $1 billion bill for US government

October 6, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cost, Heather Bresch, Misclassification, Mylan, Price hike, classification, epipen, price, scandal

Mylan’s EpiPen woes show no sign of abating after CMS (Centers for Medicare and Medicaid Services) released figures that show …

News
sicorbio

Teva to sell Allergan’s UK & Ireland generics business for $770m

October 6, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Teva

Teva has announced that it is set to sell Allergan’s UK and Ireland-based generics business for $770 million.

News
alnylambuilding-750xx1632-918-0-153

Alnylam’s shares plunge by 42% after deaths in clinical trials

October 6, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alnylam, Shares, clinical trials, deaths, failure, market value, phase III, revusiran

Alnylam Pharmaceuticals’ shares lost close to half of their value as it was forced to end a trial of its …

News
basel_site

Novartis axes 175 jobs globally in operations reshuffle

October 5, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Novartis has announced it is to shut down parts of its research operations in Switzerland and China and cutting 175 …

News
1511671_logo_1456919640

Merck’s Keytruda suffers rejection at hands of NICE

October 5, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda

NICE rejected Merck’s Keytruda, a treatment for advanced non-small-cell lung cancer (NSCLC), on the basis that the drug was not …

News
astrazeneca_plaque

AZ “disappointment” at heart drug failure

October 5, 2016
Research and Development AZ, AstraZeneca, trial failure

AstraZeneca has expressed its disappointment that its heart drug Brilinta (ticagrelor) failed to meet its primary endpoint in a recent …

News
fda_sign_web

FDA warns that certain hepatitis C drugs can have serious side-effects

October 5, 2016
Medical Communications, Research and Development FDA, hepatitis B, hepatitis C

The FDA has issued a warning to patients who are currently taking drugs to treat hepatitis C that they may …

News
1280px-epi-pen_1

Mylan’s promised half-price EpiPen not available until year’s end

October 5, 2016
Research and Development, Sales and Marketing Mylan, epipen

Consumers may have to wait until the end of the year for the half-price EpiPen, months after Mylan originally promised …

News

Roche granted breakthrough therapy designation by FDA

October 5, 2016
Research and Development Actemra, FDA, Giant Cell arteritis, Roche, breakthrough therapy

Roche has announced that the FDA has granted its Actembra drug breakthrough therapy designation for giant cell arteritis. The breakthrough …

News
jj_2johnson_and_johnson

Patients’ insulin pumps are revealed to be hackable by J&J

October 4, 2016
Research and Development, Sales and Marketing FDA, Hackers, Johnson & Johnson, diabetes, insulin

Johnson & Johnson have begun warning patients that their insulin pumps, that patients attach to their bodies and are controlled …

News
roche_side_building

Roche’s Alecensa receives second FDA Breakthrough Therapy Designation

October 4, 2016
Manufacturing and Production ALK+, Alecensa, FDA, Roche, alk, crizotinib

Alecensa has been designated as a breakthrough therapy, which will speed up the process towards FDA approval, should clinical trials …

News
astrazeneca_sign_sky

AstraZeneca’s wins major drug approval by NICE

October 4, 2016
Manufacturing and Production AstraZeneca, Cancer Drug Fund, NHS, Tagrisso

AstraZeneca’s Tagrisso (osimertinib) has successfully received endorsement of Britain’s Cancer Drugs Fund that has a reserve of £340 million to …

News
vaccine3a-062568e

Sanofi’s dengue vaccine scores 11th worldwide approval in Singapore

October 4, 2016
Sales and Marketing Sanofi, dengue, drug approval

Sanofi Pasteur, the vaccines unit of the wider French firm, has announced that its dengue vaccine Dengvaxia has secured market …

News
shutterstock_235920349

NICE and the CDF: Are they still up to scratch?

October 4, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE

Originally published in the October issue of Pharmafocus, Matt Fellows explores medical and pharmaceutical opinion of the divisive institute to …

Feature
celgene_1_02

$600m acquisition bolsters Celgene’s blood cancer portfolio

October 3, 2016
Manufacturing and Production, Research and Development Celgene, EngMab, acquisition, lymphoma, multiple myeloma

Celgene has shelled out $600m for Swiss biotech EngMab in an effort to reinforce its blood cancer portfolio with a …

News
merrimack-pharmaceuticals

Merrimack Pharmaceuticals’ CEO resigns and workforce cut by nearly a quarter

October 3, 2016
Sales and Marketing Gary Crocker, Merrimack Pharmaceuticals, Robert Mulroy

Merrimack Pharmaceuticals announced that they would cut away 22% of their workforce and their CEO, Robert Mulroy, would leave immediately …

News
The Gateway to Local Adoption Series

Latest content

Japanese pharma outsources earlier as peptide development challenges grow

April 29, 2026

Study suggests phospholipid therapy may impact fatty liver disease outcomes

April 29, 2026

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026